two
studi
involv
doubleblind
group
compar
trial
human
volunt
compar
effect
intranas
nedocromil
sodium
mg
activ
drug
per
nostril
qid
placebo
clinic
symptom
perform
impair
associ
common
cold
first
studi
volunt
challeng
rhinovirus
second
studi
respiratori
coronaviru
studi
activ
placebo
group
volunt
demograph
similar
infect
rate
group
also
similar
withdraw
result
unusu
symptom
relat
either
treatment
rhinoviru
studi
placebo
nedocromil
sodium
daili
symptom
score
daili
mean
nasal
secret
weight
significantli
lower
nedocromil
sodiumtr
group
coronaviru
studi
placebo
nedocromil
sodium
littl
differ
sever
cold
activ
placebotr
group
trend
favour
nedocromil
sodium
studi
impair
perform
volunt
develop
cold
significantli
less
treat
nedocromil
sodium
treat
placebo
topic
nedocromil
sodium
shown
benefit
prevent
treatment
asthma
man
compound
disodium
salt
pyranoquinolin
dicarboxyl
acid
inhibit
immedi
late
asthmat
reaction
result
antigen
challeng
lung
also
prevent
bronchoconstrict
caus
exercis
inhal
furthermor
reduc
season
bronchial
hyperrespons
pollensensit
subject
nedocromil
sodium
also
shown
reduc
rhiniti
induc
experiment
antigen
challeng
clinic
trial
effect
treatment
season
allerg
rhiniti
nedocromi
sodium
stabil
mucos
connect
tissu
mast
cell
alveolar
macrophag
basophil
may
improv
asthma
suppress
releas
mediat
histamin
leukotrien
prostaglandin
attempt
show
direct
measur
histamin
leukotrien
responcorrespond
r
b
wenham
fison
pic
pharmaceut
divis
loughborough
leicestershir
lei
orh
uk
sibl
part
inflammatori
respons
viral
infect
upper
respiratori
tract
unsuccess
best
inconclus
aim
present
studi
investig
effect
nedocromil
sodium
symptom
result
infect
two
differ
respiratori
virus
benefici
effecl
either
infect
would
provid
indirect
evid
one
mediat
suppress
nedocromil
sodium
play
part
symptomatolog
common
cold
caus
either
rhinoviru
type
type
coronaviru
also
shown
cold
may
impair
effici
human
perform
import
therefor
examin
whether
nedocromil
sodium
chang
clinic
symptom
also
reduc
perform
impair
associ
cold
studi
approv
harrow
district
ethic
committe
northwick
park
hospit
perform
accord
similar
protocol
healthi
volunt
either
sex
age
year
without
known
allerg
diseas
recruit
hous
isol
group
two
three
accord
normal
practic
mrc
common
cold
unit
salisburi
volunt
complet
questionnair
assess
introversionextrovers
certain
obsession
factor
shown
influenc
outcom
viru
challeng
blood
sampl
collect
subject
arriv
full
haematolog
screen
biochem
examin
includ
electrolyt
renal
liver
function
test
quarantin
period
subject
assign
randomli
number
sequenc
activ
placebo
treatment
group
code
broken
clinic
viroiog
data
report
medic
consist
one
spray
nostril
four
time
day
supervis
pm
pm
pm
day
one
hour
fifth
dose
medic
volunt
receiv
nasal
drop
contain
challeng
viru
rhinoviru
nasal
challeng
contain
estim
human
follow
similar
inoculum
hr
later
coronaviru
singl
challeng
dose
approxim
strain
studi
small
number
volunt
given
salin
instead
viru
thu
provid
inform
toler
drug
well
maintain
doubleblind
natur
ofth
trial
volunt
assess
daili
clinician
like
subject
unawar
natur
challeng
medic
receiv
sign
symptom
record
togeth
number
paper
tissu
use
previou
hr
singl
use
paper
tissu
seal
plastic
bag
five
tissu
per
bag
weigh
determin
amount
oi
nasal
secret
produc
day
end
trial
clinic
observ
score
sign
symptom
well
number
paper
tissu
use
less
averag
challeng
accord
standard
protocol
give
daili
total
score
volunt
daili
total
score
volunt
mean
daili
mean
total
score
calcul
drug
placebo
group
clinic
assess
whether
volunt
suffer
cold
doubt
cold
clinic
signific
signific
cold
mild
moder
sever
grade
made
blood
sampl
repeat
haematolog
biochem
test
collect
end
medic
anoth
request
week
later
antibodi
assay
nedocromil
sodium
isoton
solut
contain
wv
sodium
chlorid
wv
disodium
edet
wv
benzalkonium
chlorid
dispens
nasal
spray
deliv
ml
per
activ
mg
nedocromil
sodium
placebo
contain
wv
riboflavin
wv
sodium
chlorid
wv
disodium
edet
wv
benzalkonium
chlorid
dispens
similar
spray
deliv
ig
riboflavin
per
activ
nedocromil
sodium
placebo
prepar
code
fison
pic
pharmaceut
divis
nasal
wash
collect
volunt
prior
inocul
daili
day
day
inclus
inocul
mix
equal
volum
nutrient
broth
store
c
rhinoriru
lype
presenc
viru
determin
cytopath
effect
roller
tube
cultur
ohio
hela
cell
inocul
nasal
wash
least
one
isol
subject
shown
neutral
test
serotyp
one
two
challeng
virus
serum
neutral
antibodi
titr
assay
microneutr
test
fourfold
greater
rise
taken
evid
infect
coronaviru
presenc
viru
confirm
use
challeng
determin
characterist
cytopath
effect
produc
cell
concentr
serum
antibodi
follow
challeng
assay
elisa
test
measur
arbitrari
unit
comparison
standard
serum
increas
lo
unit
greater
convalesc
serum
compar
prechalleng
serum
taken
evid
infect
volunt
test
prechalleng
period
symptom
observ
usual
day
test
use
two
choic
reaction
time
task
develop
broadbent
perform
shown
impair
cold
subject
carri
trial
task
clinic
viroiog
data
analys
use
mannwhitney
ttest
fischer
exact
test
signific
level
data
test
former
also
analys
use
mackskil
statist
examin
differ
adjust
block
factor
studi
block
factor
prestudi
antibodi
level
split
three
strata
perform
test
data
analys
covari
perform
prechalleng
score
covari
statist
techniqu
take
account
baselin
differ
assess
effect
ill
drug
fiftyf
volunt
attend
three
trial
ten
volunt
exclud
either
wild
cold
contact
one
abnorm
result
haematolog
biochem
test
two
unabl
complet
trial
one
accid
one
social
reason
ofth
remaind
inocul
virus
four
salin
salin
recipi
three
volunt
receiv
placebo
one
volunt
receiv
nedocromil
sodium
three
ofth
four
record
suffer
cold
mean
total
score
fourth
volunt
given
placebo
mild
cold
score
viru
detect
nasal
wash
day
challeng
infect
presum
acquir
flatmat
experiment
infect
develop
cold
excret
viru
day
postchalleng
wash
collect
viru
recipi
volunt
inocul
viru
receiv
nedocromil
sodium
given
placebo
two
group
wcllbalanccd
age
sex
pretrial
antibodi
titr
introversionextrovers
score
score
obsession
factor
significantli
higher
placebo
group
tabl
volunt
given
drug
show
evid
infect
ofth
given
placebo
ten
given
drug
suffer
clinic
signific
cold
compar
ofth
receiv
placebo
compar
volunt
evid
infect
determin
viru
isol
antibodi
rise
consist
trend
receiv
nedocromil
sodium
fewer
andor
milder
symptom
although
signific
differ
overal
sever
cold
two
group
judg
clinic
grade
eight
mild
one
moder
one
sever
nedocromil
sodium
group
cotnpar
mild
two
moder
placebo
group
howev
four
doubt
cold
ie
symptom
suffici
sever
persist
enabl
firm
diagnosi
cold
made
occur
activ
drug
group
one
placebo
group
thu
infect
volunt
given
drug
upper
respiratori
symptom
compar
volunt
receiv
placebo
furthermor
mean
daili
clinic
score
mean
daili
nasal
secret
weight
lower
treat
placebo
group
fig
mean
total
clinic
score
nedocromil
sodium
group
compar
placebo
group
correspond
valu
mean
total
nasal
secret
weight
g
g
statist
signific
differ
two
group
shown
mean
clinic
score
day
p
result
perform
test
similar
rhinoviru
coronaviru
trial
summar
end
result
section
coronaviru
trial
sixtythre
volunt
attend
five
trial
took
part
studi
one
volunt
exclud
hay
fever
anoth
abnorm
haematolog
biochem
test
result
famili
ill
prevent
one
volunt
complet
trial
anoth
volunt
exclud
retrospect
viru
present
prechalleng
nasal
wash
ofth
remaind
challeng
viru
six
salin
salin
recipi
four
volunt
receiv
placebo
two
receiv
nedocromil
sodium
ill
experienc
volunt
mean
total
clinic
score
receiv
nedocromil
sodium
compar
given
placebo
viru
recipi
twentyseven
volunt
challeng
viru
receiv
nedocromil
sodium
given
placebo
one
given
nedocromil
sodium
femal
two
group
wellbalanc
age
pretrial
antibodi
titr
score
obsession
factor
extrovers
higher
placebo
drug
group
reach
statist
signific
tabl
laboratori
evid
infect
obtain
rio
ofth
volunt
given
drug
receiv
placebo
nine
ofth
volunt
given
drug
receiv
placebo
suffer
clinic
signific
cold
doubt
cold
also
includ
volunt
upper
respiratori
symptom
group
littl
clinic
differ
sever
thecoldsin
twogroup
two
moder
seven
mild
seven
doubt
nedocromil
sodium
group
compar
two
moder
mild
four
doubt
placebo
group
among
infect
volunt
direct
relationship
mean
daili
clinic
score
mean
daili
nasal
secret
weight
medic
fig
howev
mean
total
clinic
score
placebo
group
higher
drug
group
revers
true
mean
total
nasal
secret
weight
g
nedocromil
sodium
group
g
placebo
group
clinic
observ
statist
signific
differ
p
demonstr
nasal
secret
weight
day
result
perform
test
similar
rhinoviru
coronaviru
trial
mean
reaction
time
differ
condit
shown
tabl
subject
given
nedocromil
sodium
clinic
assess
cold
impair
perform
less
subject
given
placebo
howev
subject
receiv
nedocromil
sodium
evid
cold
reaction
time
increas
result
signific
interact
coldsno
cold
drugplacebo
condit
intranas
nedocromil
sodium
appear
well
toler
volunt
receiv
nedocromil
sodium
without
viru
challeng
evid
local
irrit
haematolog
biochem
test
perform
treatment
within
normal
limit
significantli
differ
receiv
placebo
treatment
nedocromil
sodium
effect
frequenc
viru
shed
either
studi
serolog
respons
viru
expect
nedocromil
sodium
shown
laboratori
antivir
activ
rhinovirusc
tissu
cultur
therhinovirustrialit
possibl
imbal
obsession
symptom
score
two
group
tabl
rather
drug
could
account
differ
mean
clinic
score
mean
nasal
secret
weight
howev
studi
correl
obsession
score
nasai
secret
weight
clinic
score
volunt
includ
neg
correl
demonstr
volunt
within
placebo
group
therefor
conclud
reduc
mean
daili
clinic
score
secret
weight
attribut
action
nedocromil
sodium
correct
cold
would
classifi
signific
without
drug
might
assess
doubt
cold
drug
given
rhinoviru
trial
ofth
infect
subject
receiv
placebo
develop
signific
cold
compar
given
drug
howev
doubt
cold
includ
placebo
recipi
symptom
compar
given
drug
reason
could
argu
remain
differ
could
account
nedocromil
sodium
suppress
symptom
extent
would
diagnos
doubt
cold
record
cold
coronaviru
studi
fewer
volunt
show
evid
infect
rhinoviru
trial
given
nedocromil
sodium
nine
compar
receiv
placebo
suffer
clinic
signific
cold
howev
rhinoviru
trial
doubt
cold
includ
volunt
group
upper
respiratori
symptom
littl
differ
mean
clinic
score
treatment
group
despit
differ
nasal
secret
weight
increas
nasal
secret
reflect
increas
use
paper
tissu
later
contribut
heavili
clinic
score
coronaviru
trial
although
mean
total
nasai
secret
weight
greater
nedocromil
sodium
group
placebo
group
correspond
increas
mean
total
clinic
score
thu
suggest
nedocromil
sodiutn
reduc
symptom
cold
nasal
secret
result
studi
suggest
nedocromil
sodium
partial
prevent
ofth
symptom
cold
caus
rhinovirus
lesser
extent
coronavirus
mediat
suppress
drug
role
symptomatolog
cold
differ
rhinoviru
coronaviru
infect
incub
period
lead
appear
symptom
longer
coronaviru
clinic
amount
nasal
secret
main
featur
distinguish
coronaviru
rhinoviru
cold
suggest
mechan
nasal
secret
stimul
differ
could
account
differ
respons
drug
two
type
infect
possibl
howev
nedocromii
sodium
block
mediat
releas
entir
symptom
sign
infect
complet
suppress
analog
breakthrough
symptom
may
occur
treatment
season
allerg
rhiniti
includ
studi
measur
perform
chang
subject
report
elsewher
minor
respiratori
infect
associ
measur
substanti
declin
human
perform
declin
specif
exampl
cold
impair
perform
task
measur
handey
coordin
requir
attent
trial
nedocromil
sodium
prevent
loss
perform
subject
suffer
clinic
symptom
cold
although
explan
known
volunt
given
drug
develop
cold
show
slower
perform
without
cold
given
placebo
moment
unclear
exactli
respons
effect
rhinoviru
trial
volunt
subclin
infect
drug
group
compar
placebo
group
previou
studi
shown
even
subclin
infect
may
impair
perform
could
one
factor
contribut
slower
respons
time
coldsdrug
group
viral
infect
upper
respiratori
tract
precipit
exacerb
asthma
increas
airway
respons
asthmat
patient
well
normal
subjest
although
find
question
other
nedocromil
sodium
inhibit
releas
mediat
inflammatori
cell
reduc
inflamm
ofth
airway
associ
asthma
could
similar
mechan
account
benefici
effect
shown
nedocromil
sodium
symptomatolog
experiment
cold
recent
studi
report
common
cold
unit
fail
show
rais
level
histamin
mediat
implic
asthma
nasal
secret
subject
follow
viral
inocul
howev
inabl
detect
mediat
direct
method
exclud
play
role
albeit
minor
common
cold
present
knowledg
ofth
mode
action
nedocromil
togeth
reduct
observ
symptomolog
rhinoviru
coronaviru
infect
volunt
given
compound
suggest
mediat
may
respons
symptom
upper
respiratori
viral
infect
